0LB2 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Supernus Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 48.03 USD 0.17% Market Closed

Market Cap: $2.8B

	Supernus Pharmaceuticals Inc LSE:0LB2	US
	Vicat SA PAR:VCT	FR
P	Pharol SGPS SA ELI:PHR	PT
	AXA SA MIL:1CS	FR
	Seek Ltd ASX:SEK	AU
T	Tandem Diabetes Care Inc LSE:0M0F	US
H	Henkel AG & Co KGaA SWB:HEN	DE
	Taylor Devices Inc NASDAQ:TAYD	US
	Federal Realty Investment Trust NYSE:FRT	US
	Centessa Pharmaceuticals PLC NASDAQ:CNTA	UK
	Roche Holding AG OTC:RHHBY	CH
	Siemens Healthineers AG F:SHL	DE
G	General Mills Inc XBER:GRM	US
R	Rockwell Automation Inc XMUN:RWL	US
S	SeaStar Medical Holding Corp NASDAQ:ICU	US
M	Mitsubishi UFJ Financial Group Inc XMUN:MFZ	JP
	ILPRA SpA MIL:ILP	IT
	Bank of America Corp NYSE:BAC	US
T	Telekom Austria AG XBER:TA1	AT

Profitability Summary

Supernus Pharmaceuticals Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

90%

Strong 3Y Average Gross Margin

88%

Gross Margin is Increasing

85% > 90%

Negative Operating Margin

-8%

Low 3Y Average Operating Margin

Declining Operating Margin

3% > -8%

Negative Net Margin

-4%

Low 3Y Average Net Margin

Declining Net Margin

7% > -4%

Exceptional Free Cash Flow Margin

11%

Strong 3Y Average Free Cash Flow Margin

18%

Declining Free Cash Flow Margin

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.